Compass Therapeutics enters ATM with Jefferies for up to $75M; terminates B. Riley facility

Compass Therapeutics, Inc.

Enters Open Market Sale Agreement with Jefferies to sell up to $75M of common stock via ATM offering.
Prior ATM agreement with B. Riley Securities terminated effective July 29, 2022.
Jefferies receives up to 3% commission and up to $75K expense reimbursement; Compass not obligated to sell.
Sales will be made under effective S-3 registration statement (333-257821) and prospectus supplement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.